Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation.

BMC neuroscience - 13 Jan 2005

Wang Jin, Gines Silvia, MacDonald Marcy E, Gusella James F

Abstract excerpt

BACKGROUND: Huntington's disease (HD) is an inherited neurodegenerative disorder triggered by an expanded polyglutamine tract in huntingtin that is thought to confer a new conformational property on this large protein. The propensity of small amino-terminal fragments with mutant, but not wild-type, glutamine tracts to self-aggregate is consistent with an altered conformation but such fragments occur relatively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Aggregation
Share to Cell Line, Transformed

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Corpus Striatum

Share to Drug Evaluation, Preclinical

Share to Huntingtin Protein

Share to Mice, Mutant Strains

Share to Mutant Proteins

Share to Peptides

Source

Open in PubMed Open full text

Identifiers

PMID: 15649316
DOI: 10.1186/1471-2202-6-1
PMCID: PMC548150

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation.PMID 15649316Read ↗

Huntington's disease: from pathology and genetics to potential therapies.Semantic proximity Read ↗

Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.Semantic proximity Read ↗

Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington’s diseaseSemantic proximity Read ↗

Molecular mechanisms and potential therapeutical targets in Huntington's disease.Semantic proximity Read ↗

Monomeric, Oligomeric and Polymeric Proteins in Huntington Disease and Other Diseases of Polyglutamine ExpansionSemantic proximity Read ↗

Anle138b ameliorates pathological phenotypes in mouse and cellular models of Huntington's disease.Semantic proximity Read ↗

A Review On Huntington Protein: Insight Into Protein Aggregation and Therapeutic Interventions.Semantic proximity Read ↗

Huntington's disease: From molecular basis to therapeutic advances.Semantic proximity Read ↗

Huntington's disease: molecular basis of neurodegeneration.Semantic proximity Read ↗

Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteinsSemantic proximity Read ↗

Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In VivoSemantic proximity Read ↗

Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.